This substitution blocks a major cleavage site of activated protein C (APC), thereby resulting in a decreased ability of APC to inactivate the procoagulant factor Va which result in hypercoaguable state that leads to an increased risk for venous thromboembolism. This evidence concerns the gene APC and venous thromboembolism.